Istradefylline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Istradefylline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
42
Registered trials
15
Result records
24
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Istradefylline can convert its Small molecule drug profile and A2aR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Istradefylline (query alias: istradefylline) |
|---|---|
| Modality / target | Small molecule drug; A2aR; A2aR antagonists |
| Highest global status | Approved |
| Originator | Kyowa Kirin Co., Ltd. |
| Active developers | Kyowa Kirin, Inc., Piston Bio LLC, Kyowa Kirin Co., Ltd. |
The MCP disease footprint includes Parkinson Disease, Primary Parkinson's disease, Mild cognitive disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05885360 | Phase 4 | Completed | 27 | To observe the effect of Istradefylline on tremor in PD patients. |
| CTR20230645 | Phase 3 | 主动终止 | 253 | Not disclosed |
| JPRN-jRCTs051250026 | Phase 2 | Recruiting | 20 | Yale-Brown強迫観念・強迫行為尺度（Y-BOCS） |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
Not Applicable; n=2045; evaluation: Positive. Reported fields: Median persistence = 365.0 Day ( 90 - 365); Median persistence = 276.0 Day ( 90 - 365)
Comparative Safety of Istradefylline Among Parkinson’s Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies (P5-3.017)
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: hallucinations = The odds of hallucinations were significantly higher for amantadine vs. istradefylline at 40 and 20mg ; Adverse Event: hallucinations = The odds of hallucinations were significantly higher for amantadine vs. istradefylline at 40 and 20mg ; Adverse Event: hallucinations = The odds of hallucinations were significantly higher for amantadine vs. istradefylline at 40 and 20mg
Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)
Phase 3; n=214; evaluation: Positive. Reported fields: Incidence of dyskinesia = 41.1 % ; Incidence of dyskinesia = 37.9 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Istradefylline addresses Parkinson Disease, Primary Parkinson's disease, Mild cognitive disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 24 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: A2aR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-06-14 | Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas | Approved | Financial terms not disclosed |
| 2023-04-12 | 思路迪医药与英诺湖医药达成战略合作协议 | Approved | Financial terms not disclosed |
| 2022-07-01 | Portage Biotech to purchase Tarus Therapeutics' TT-10 (now PORT-6), TT-4 (now PORT-7), TT-53 (now PORT-8), and TT-3 (now PORT-9) for the treatment of solid tumors, cancer, and other ailments. | Preclinical | US$21.0M upfront; US$32.0M milestones; US$53.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Adenosine a2a receptor antagonists to treat REM sleep behavior disorder and prevent synucleinopathies”. The milestone feed surfaced a patent-application signal described as “Method for detecting residual solvent in istradefylline bulk drug”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical application of compound istradefylline for reversing drug resistance of paclitaxel”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
